Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma. 1996

G J Wiedemann, and H I Robins, and S Gutsche, and M Mentzel, and M Deeken, and D M Katschinski, and S Eleftheriadis, and R Crahé, and C Weiss, and B Storer, and T Wagner
Department of Internal Medicine, Medical University of Lübeck, Germany.

Two earlier studies resulted in the design of a phase II trial of 41.8 degrees C (x 60 min) extracorporeal whole body hyperthermia (WBH) with ICE, i.e. ifosfamide (5 g/m2), carboplatin (300 mg/m2), and etoposide given with WBH, as well as, day 2 and 3 post-WBH (100 mg/m2) for adult patients with refractory sarcoma. 12 patients entered this trial; all were evaluable. 8 patients had a history of prior chemotherapy associated with disease progression. Following WBH/ICE, 7 partial remissions were observed (58%); 3 patients experienced disease stabilisation; the aforementioned 10 patients each received four cycles of therapy. 2 patients exhibited progressive disease. Episodes of WHO graded (grade 3; grade 4) toxicity observed included: anaemia (2;2); leucopenia (5;7); thrombocytopenia (1;6); renal (0;1). Other toxicities (grade 1 and 2) included: anasarca, diarrhoea, ventricular arrhythmias, pressure sores, and perioral herpes simplex.

UI MeSH Term Description Entries
D006979 Hyperthermia, Induced Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs. Fever Therapy,Hyperthermia, Local,Hyperthermia, Therapeutic,Thermotherapy,Induced Hyperthermia,Therapeutic Hyperthermia,Therapy, Fever,Local Hyperthermia
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

G J Wiedemann, and H I Robins, and S Gutsche, and M Mentzel, and M Deeken, and D M Katschinski, and S Eleftheriadis, and R Crahé, and C Weiss, and B Storer, and T Wagner
October 1994, Cancer research,
G J Wiedemann, and H I Robins, and S Gutsche, and M Mentzel, and M Deeken, and D M Katschinski, and S Eleftheriadis, and R Crahé, and C Weiss, and B Storer, and T Wagner
April 2004, Pneumologie (Stuttgart, Germany),
G J Wiedemann, and H I Robins, and S Gutsche, and M Mentzel, and M Deeken, and D M Katschinski, and S Eleftheriadis, and R Crahé, and C Weiss, and B Storer, and T Wagner
September 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
G J Wiedemann, and H I Robins, and S Gutsche, and M Mentzel, and M Deeken, and D M Katschinski, and S Eleftheriadis, and R Crahé, and C Weiss, and B Storer, and T Wagner
May 1993, Journal of the National Cancer Institute,
G J Wiedemann, and H I Robins, and S Gutsche, and M Mentzel, and M Deeken, and D M Katschinski, and S Eleftheriadis, and R Crahé, and C Weiss, and B Storer, and T Wagner
January 1999, Cancer chemotherapy and pharmacology,
G J Wiedemann, and H I Robins, and S Gutsche, and M Mentzel, and M Deeken, and D M Katschinski, and S Eleftheriadis, and R Crahé, and C Weiss, and B Storer, and T Wagner
January 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
G J Wiedemann, and H I Robins, and S Gutsche, and M Mentzel, and M Deeken, and D M Katschinski, and S Eleftheriadis, and R Crahé, and C Weiss, and B Storer, and T Wagner
January 1999, Cancer chemotherapy and pharmacology,
G J Wiedemann, and H I Robins, and S Gutsche, and M Mentzel, and M Deeken, and D M Katschinski, and S Eleftheriadis, and R Crahé, and C Weiss, and B Storer, and T Wagner
January 2020, Sarcoma,
G J Wiedemann, and H I Robins, and S Gutsche, and M Mentzel, and M Deeken, and D M Katschinski, and S Eleftheriadis, and R Crahé, and C Weiss, and B Storer, and T Wagner
April 2023, Blood advances,
G J Wiedemann, and H I Robins, and S Gutsche, and M Mentzel, and M Deeken, and D M Katschinski, and S Eleftheriadis, and R Crahé, and C Weiss, and B Storer, and T Wagner
October 2005, European journal of applied physiology,
Copied contents to your clipboard!